

Acalabrutinib

Art. ID TRC-A115605-25MG
Unit 25 mg

Description

"Application Notes: Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL). // References: Byrd| et al. (2015). ""Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.""| ""AstraZeneca to buy Acerta for blood cancer drug"". www.rsc.org. Chemistry World - Royal Society of Chemistry. Retrieved 24 December 2015."

Text/Information	Analyte/Parameter	CAS number	Concentration/Value	Unit	Method	Source
	Acalabrutinib	[1420477-60-6]				